Cover
Vol. 4 No. 1 (2026)

Published: June 1, 2026

Pages: 34-48

Research Article

In-Silico Profiling of New Mefenamic Acid Derivatives as HDAC 8 Inhibitors

Zainab Ali 1 Mohammed J Hamzah 1 Ameer H. Alwash 2
1 Department of Pharmaceutical Chemisrty , College of Pharmacy, Al-Nahrain University, Baghdad, Iraq
2 Department of Pharmaceutical Chemisrty , College of Pharmacy, Al-Bayan University, Baghdad, Iraq
History
  • Received: January 8, 2026
  • Revised: March 9, 2026
  • Accepted: March 15, 2026
  • Available Online: June 1, 2026

Abstract

Vital cellular processes such as, proliferation and tumor progression were reported to be centrally controlled by histone deacetylase (HDAC) enzymes which make them an interesting therapeutic target. Recently, a new paradigm has attracted researches to combine nonsteroidal anti-inflammatory drugs (NSAIDs) with para-aminobenzoic acid (PABA) and a zinc binding group (ZBG), presenting a synergistic impact on HDAC activity and inflammatory process. In the current study, a novel series of hybrid compounds (A1-6) were designed and evaluated for their HDAC binding affinity by molecular docking technique along with conducting an in-silico ADME (absorption, distribution, metabolism, and elimination) profiling to assess their pharmacokinetic characteristics. Compound A6 displayed the highest binding energy score (-9.539 kcal/mol) with the active site of HDAC 8 enzyme compared with the reference ligand, SAHA (-4.606 kcal/mol). Its worth mentioning that compound A6 has comparable coordination to the catalytic zinc ion with SAHA along with engaging additional hydrophobic and aromatic interaction within the active site of HDAC 8 enzyme. ADME analysis predicated high gastrointestinal absorption for A2, A5, and A6, which also comply with Lipinski's rule, indicating good oral bioavailability. Conversely, A1, A3, and A4 showed moderate absorption, suitable for parenteral or localized/colon-targeted delivery, potentially advantageous for colon cancer treatment. These results highlight these hybrids’ potential as HDAC inhibitors and support further synthesis and biological testing.

Keywords

References

  1. Xu Y, Tang H, Xu Y, Guo J, Zhao X, Meng Q, et al. Design, synthesis, bioactivity evaluation, crystal structures, and in silico studies of new α-amino amide derivatives as potential histone deacetylase 6 inhibitors. Molecules. 2022;27(10):3335.
  2. Raucci A, Zwergel C, Valente S, Mai A. Advancements in Hydrazide-Based HDAC Inhibitors: A Review of Recent Developments and Therapeutic Potential. Journal of Medicinal Chemistry. 2025;68(14):14171-94.
  3. Ahmad B, Saeed A, Al-Amery A, Celik I, Ahmed I, Yaseen M, et al. Investigating potential cancer therapeutics: insight into histone deacetylases (HDACs) inhibitions. Pharmaceuticals. 2024;17(4):444.
  4. Kim JH, Ali KH, Oh YJ, Seo YH. Design, synthesis, and biological evaluation of histone deacetylase inhibitor with novel salicylamide zinc binding group. Medicine. 2022;101(17):e29049.
  5. Tian J, Han M, Song F, Liu Y, Shen Y, Zhong J. Advances of HDAC inhibitors in tumor therapy: potential applications through immune modulation. Frontiers in Oncology. 2025;15:1576781.
  6. Yudaev P, Aleksandrova Y, Neganova M. Recent Insights into the Creation of Histone Deacetylase Inhibitors for the Treatment of Human Diseases. International Journal of Molecular Sciences. 2025;26(17):8629.
  7. Pires GS, Tolomeu HV, Rodrigues DA, Lima LM, Fraga CAM, Pinheiro PdSM. Drug Discovery for Histone Deacetylase Inhibition: Past, Present and Future of Zinc-Binding Groups. Pharmaceuticals. 2025;18(4):577.
  8. Bondarev AD, Attwood MM, Jonsson J, Chubarev VN, Tarasov VV, Schiöth HB. Recent developments of HDAC inhibitors: Emerging indications and novel molecules. British journal of clinical pharmacology. 2021;87(12):4577-97.
  9. Morales-Herrejón G, García-Vázquez JB, Fernández-Pomares C, Bakalara N, Correa-Basurto J, Mendoza-Figueroa HL. Computationally Guided Design, Synthesis, and Evaluation of Novel Non-Hydroxamic Histone Deacetylase Inhibitors, Based on N-Trifluoroacetamide as a Zinc-Binding Group, Against Breast Cancer. Pharmaceuticals. 2025;18(3):351.
  10. Liu W-B, Song J, Zhang S-Y. A short overview of dual targeting HDAC inhibitors. Future Medicinal Chemistry. 2025;17(1):5-7.
  11. Alrouji M, Venkatesan K, Alshammari MS, Alhumaydhi FA, Shafi S, Sharaf SE, et al. Repurposed drugs as histone deacetylase 8 inhibitors: Implications in cancer and neuropathological conditions. Frontiers in Pharmacology. 2024;15:1488585.
  12. Asfaha Y, Skerhut AJ, Alves-Avelar LA, Horstick-Muche N, Lungerich B, Klinken S, et al. Synthesis of thiazolyl-based hydroxamic acids as histone deacetylase inhibitors. Arkivoc. 2020;7:228-41.
  13. Useini L, Mojic M, Laube M, Lönnecke P, Dahme J, Sárosi MB, et al. Carboranyl analogues of mefenamic acid and their biological evaluation. ACS omega. 2022;7(28):24282-91.
  14. Mustafa H, Daud S, Sheraz S, Bibi M, Ahmad T, Sardar A, et al. The Chemistry and Bioactivity of Mefenamic Acid Derivatives: A Review of Recent Advances. Archiv der Pharmazie. 2025;358(5):e70004.
  15. Milusheva M, Todorova M, Gledacheva V, Stefanova I, Feizi-Dehnayebi M, Pencheva M, et al. Novel anthranilic acid hybrids—an alternative weapon against inflammatory diseases. Pharmaceuticals. 2023;16(12):1660.
  16. Drakontaeidi A, Pontiki E. A review on molecular docking on HDAC isoforms: Novel tool for designing selective inhibitors. Pharmaceuticals. 2023;16(12):1639.
  17. Yang Y, Chen S, Wang Q, Niu M-M, Qu Y, Zhou Y. Identification of novel and potent dual-targeting HDAC1/SPOP inhibitors using structure-based virtual screening, molecular dynamics simulation and evaluation of in vitro and in vivo antitumor activity. Frontiers in Pharmacology. 2023;14:1208740.
  18. Adewole K, Ishola A, Olaoye I. In silico profiling of histone deacetylase inhibitory activity of compounds isolated from Cajanus cajan. Beni-Suef University Journal of Basic and Applied Sciences. 2022;11(1):9.
  19. Gopinathan A, Sankhe R, Rathi E, Kodi T, Upadhya R, Pai KSR, et al. An in silico drug repurposing approach to identify HDAC1 inhibitors against glioblastoma. Journal of Biomolecular Structure and Dynamics. 2024:1-14.
  20. Debnath S, Debnath T, Bhaumik S, Majumdar S, Kalle AM, Aparna V. Discovery of novel potential selective HDAC8 inhibitors by combine ligand-based, structure-based virtual screening and in-vitro biological evaluation. Scientific Reports. 2019;9(1):17174.
  21. Roos K, Wu C, Damm W, Reboul M, Stevenson JM, Lu C, et al. OPLS3e: Extending force field coverage for drug-like small molecules. Journal of chemical theory and computation. 2019;15(3):1863-74.
  22. Vema A, Debnath S, Kalle AM. Identification of novel HDAC8 selective inhibitors through ligand and structure based studies: Exploiting the acetate release channel differences among class I isoforms. Arabian Journal of Chemistry. 2022;15(6):103863.
  23. Ganai SA, Abdullah E, Rashid R, Altaf M. Combinatorial in silico strategy towards identifying potential hotspots during inhibition of structurally identical HDAC1 and HDAC2 enzymes for effective chemotherapy against neurological disorders. Frontiers in molecular neuroscience. 2017;10:357.
  24. Nurani A, Yamashita Y, Taki Y, Takada Y, Itoh Y, Suzuki T. Identification of a histone deacetylase 8 inhibitor through drug screenings based on machine learning. Chemical and Pharmaceutical Bulletin. 2024;72(2):173-8.